172 related articles for article (PubMed ID: 8004758)
61. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
62. Combined modalities of resistance in etoposide-resistant human KB cell lines.
Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC
Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393
[TBL] [Abstract][Full Text] [Related]
63. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
de Jong S; Zijlstra JG; Mulder NH; de Vries EG
Cancer Chemother Pharmacol; 1991; 28(6):461-4. PubMed ID: 1657425
[TBL] [Abstract][Full Text] [Related]
64. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
65. Reduced topoisomerase II-mediated DNA cleavage in VP-16 resistant human leukemic cell line.
Saijo Y; Satoh K; Tokue Y; Kumano N; Motomiya M
Anticancer Res; 1991; 11(1):445-8. PubMed ID: 1850222
[TBL] [Abstract][Full Text] [Related]
66. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Austin CA; Fisher LM
Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
[TBL] [Abstract][Full Text] [Related]
67. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
68. [Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines].
Takigawa N; Ohnoshi T; Ueoka H; Yonei T; Kiura K; Tabata M; Kodani T; Kamei H; Segawa Y; Shibayama T
Gan To Kagaku Ryoho; 1993 May; 20(7):929-35. PubMed ID: 8387762
[TBL] [Abstract][Full Text] [Related]
69. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells.
Smith PJ; Morgan SA; Fox ME; Watson JV
Biochem Pharmacol; 1990 Nov; 40(9):2069-78. PubMed ID: 2173600
[TBL] [Abstract][Full Text] [Related]
70. [Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines].
Matsumoto Y; Takano H; Nagao S; Iglesias A; Fojo T
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2265-9. PubMed ID: 9422071
[TBL] [Abstract][Full Text] [Related]
71. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression.
Henness S; Davey MW; Harvie RM; Davey RA
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):895-902. PubMed ID: 12377343
[TBL] [Abstract][Full Text] [Related]
72. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
Harker WG; Slade DL; Drake FH; Parr RL
Biochemistry; 1991 Oct; 30(41):9953-61. PubMed ID: 1655025
[TBL] [Abstract][Full Text] [Related]
73. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
Hong JH
Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562
[TBL] [Abstract][Full Text] [Related]
74. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
De Isabella P; Capranico G; Binaschi M; Tinelli S; Zunino F
Mol Pharmacol; 1990 Jan; 37(1):11-6. PubMed ID: 2153905
[TBL] [Abstract][Full Text] [Related]
75. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Basu A; Weixel K; Saijo N
Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400
[TBL] [Abstract][Full Text] [Related]
76. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
77. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
[TBL] [Abstract][Full Text] [Related]
78. [Influence of interference of WIG-1 on the multi-drug resistance in small cell lung cancer].
Luo S; Bai Y; Lan H
Zhonghua Zhong Liu Za Zhi; 2014 Oct; 36(10):733-8. PubMed ID: 25567302
[TBL] [Abstract][Full Text] [Related]
79. "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).
Cimoli G; Valenti M; Noviello E; Parodi S; Mazzoni A; Rovini E; De Sessa F; Russo P
J Cancer Res Clin Oncol; 1995; 121(3):155-63. PubMed ID: 7713987
[TBL] [Abstract][Full Text] [Related]
80. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
